Mylan Pharmaceuticals has issued a voluntary recall of the commonly prescribed anxiety medication Xanax, citing the possibility of a "foreign substance" in a batch of the drug.
The announcement came last week as the company acknowledged that one lot of its Alprazolam tablets (Xanax) potentially carries a substance with a remote risk of infection.
- RELATED ARTICLES
- Philadelphia saved billions of dollars with syringe exchange programs, study says
- Flavored e-cigarettes lead to heavier use among teens, study says
- Bariatric surgery found safe for teens with morbid obesity, study says
"Clinical impact from the foreign material, if present, is expected to be rare, but the remote risk of infection to a patient cannot be ruled out," the company said in a statement. "To date, Mylan has not received any adverse events related to this batch."
Mylan did not provide any additional information about the substance it detected.
Wholesalers, retailers and consumers have been provided with instructions for how to return recalled medication and how to report adverse events.